Company Announcement no. 6/2015
To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, 3 March 2015
Warrant Programme - New Articles of Association
In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of Directors of Veloxis Pharmaceuticals A/S has on 3 March 2015 issued 23,700,842 warrants for the subscription of nominally DKK 2,370,084.20 shares in the Company.
The amendment of the Articles of Association associated with the issue of warrants has today been registered with the Danish Business Authority. The new Articles of Association are for Veloxis Pharmaceuticals A/S are attached.
For more information, please contact:
Veloxis Pharmaceuticals A/S
Bill Polvino Johnny Stilou
President & CEO EVP, Chief Financial Officer
Phone: +1 732 321 3202 Phone: +45 30 53 33 64
Email: wjp@veloxis.com Email: jst@veloxis.com
About Veloxis Pharmaceuticals
Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis’ unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.
